Moderna to Report First Quarter Financial Results on Wednesday, August 3, 2022

Rhea-AI Summary

Moderna (NASDAQ:MRNA) announced a live conference call on August 3, 2022, at 8:00 a.m. ET to discuss its second quarter 2022 financial results and provide a corporate update. Investors can access the call via telephone or webcast through the company's website. This event will include insights into Moderna's ongoing advancements in mRNA therapeutics and the development of vaccines against infectious diseases, including COVID-19. An archived version of the call will be available shortly after its conclusion.

Positive

• Continued advancements in mRNA therapeutics and vaccines.
• Diverse clinical portfolio across seven modalities.

Negative

• None.

CAMBRIDGE, MA / ACCESSWIRE / July 13, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, August 3, 2022 to report its second quarter 2022 financial results, and provide a corporate update.

To access the live conference call via telephone, please register at the link below. Once registered, dial-in numbers and a unique pin number will be provided. A live webcast of the call will also be available under "Events and Presentations" in the Investors section of the Moderna website.

• Telephone: https://register.vevent.com/register/BI56aa5dacc77e41ebbba622851ac67f30
• Webcast: https://investors.modernatx.com

The archived webcast will be available on Moderna's website approximately two hours after the conference call and will be available for one year following the call.

About Moderna

In over 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators. Most recently, Moderna's capabilities have come together to allow the authorized use and approval of one of the earliest and most effective vaccines against the COVID-19 pandemic.

Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past seven years. To learn more, visit www.modernatx.com.

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com

SOURCE: Moderna, Inc.

View source version on accesswire.com:
https://www.accesswire.com/708296/Moderna-to-Report-First-Quarter-Financial-Results-on-Wednesday-August-3-2022

FAQ

What date is Moderna reporting its second quarter 2022 financial results?

Moderna will report its second quarter 2022 financial results on August 3, 2022.

How can I access Moderna's conference call?

You can access Moderna's conference call by registering through the provided link or via their website's Events and Presentations section.

What time will the conference call take place?

The conference call will take place at 8:00 a.m. ET.

Will there be an archived version of the conference call?

Yes, an archived version of the conference call will be available on Moderna's website approximately two hours after the call.

What is the significance of Moderna's mRNA technology?

Moderna's mRNA technology has been pivotal in developing therapeutics and vaccines for various diseases, including COVID-19.